0001209191-22-033544.txt : 20220602 0001209191-22-033544.hdr.sgml : 20220602 20220602163651 ACCESSION NUMBER: 0001209191-22-033544 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220531 FILED AS OF DATE: 20220602 DATE AS OF CHANGE: 20220602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zeronda Tyler CENTRAL INDEX KEY: 0001867033 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 22991365 MAIL ADDRESS: STREET 1: C/O VYNE THERAPEUTICS STREET 2: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VYNE Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-31 0 0001566044 VYNE Therapeutics Inc. VYNE 0001867033 Zeronda Tyler C/O VYNE THERAPEUTICS, INC. 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 0 1 0 0 CFO Common Stock 2022-05-31 5 A 0 E 12510 0.3463 A 174066 D These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2021 and ending on May 31, 2022 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2022 (the last trading day of the offering period). /s/ Mutya Harsch, attorney-in-fact for Tyler Zeronda 2022-06-02